.jpg?format=webp&width=780)
Several reports have suggested that PD1/PD‐L1 inhibitors could restore platinum sensitivity in metastatic urothelial carcinoma (mUC). Therefore, they investigated the real‐world outcomes to assess the clinical benefit of re‐challenging chemotherapy after pembrolizumab. A median overall survival (OS) from PD for pembrolizumab was 11 months in 105 patients. Of 25 patients treated with re‐challenging chemotherapy, platinum‐including chemotherapy (GC, GCP, MVAC, and MCAVI) were offered in 20 patients (80%). Re‐challenging chemotherapy, including platinum agents after PD of pembrolizumab, offers clinical benefits in mUC patients.
Like
Save
Share